INTRODUCTION
============

Breast cancer is the second most common malignancy in women in the United States after skin cancer \[[@B1]\]. It is one of the primary causes of cancer-related death in women worldwide and the fifth leading cause in Korea \[[@B2],[@B3]\]. Furthermore, the incidence of breast cancer is increasing with population aging, changing reproductive patterns, and increasingly active screening \[[@B1],[@B4]\]. Fortunately, the treatment outcomes of breast cancer have shown considerable improvement in recent decades, primarily because of stage/subtype-specific multi-modality treatment \[[@B1],[@B4]\].

Postoperative radiotherapy (PORT) is one of the essential breast cancer treatment modalities, and a positive effect of PORT after breast-conserving surgery (BCS) has clearly been demonstrated in a large long-term study \[[@B5]\]. Because of these proven benefits, PORT is recommended for all breast cancer patients who receive BCS \[[@B6],[@B7]\]. However, some patients do not receive PORT for various reasons, such as a fear of radiation, difficulty in accessing a radiation facility, or short life expectancy. According to the Surveillance, Epidemiology, and End Results (SEER) registry, approximately 10% to 20% of patients did not receive PORT after BCS \[[@B8]\], and those patients had lower cancer-specific survival than patients who did receive PORT \[[@B9]\]. On the other hand, studies have indicated that some patients can omit PORT without an increase in their recurrence risk \[[@B10],[@B11],[@B12],[@B13],[@B14]\]. The clinical outcomes of PORT omission after BCS have not been studied in a Korean population.

The present study was designed to investigate the proportion and clinical outcomes of breast cancer patients who did not receive PORT after BCS at Samsung Medical Center in Korea.

METHODS
=======

The present retrospective study was conducted on all breast cancer patients who received curative BCS at Samsung Medical Center between January 2003 and June 2013. Our Institutional Review Board approved this study and waived the requirement for consent (IRB number: 2014-07-020).

The inclusion criteria were as follows: female patients who were pathologically diagnosed with invasive breast cancer, no distant metastasis (DM) detected before surgery and for at least 6 months after surgery, and curative BCS performed without subsequent adjuvant radiotherapy (RT) within 1 year. The ineligibility criteria were as follows: presence of *in situ* lesion(s) only, ipsilateral tumor recurrence after curative local treatment, completion of total mastectomy within 6 months after BCS, prior or simultaneous invasive malignancy except for papillary thyroid carcinoma, and/or minimum 2-year disease-free interval.

This study was based on all registered data coded as invasive breast cancer in the Samsung Medical Center Information System based on the above criteria. Initially, we searched for patients who were diagnosed with invasive breast cancer and who received resection surgery in our hospital without a record of RT in the following year. Patients who underwent a total mastectomy or completed mastectomy after BCS were excluded. For all remaining patients, we confirmed whether PORT was conducted in another institution through a careful review of medical records, and we excluded patients with confirmed definite administration of PORT. The present study was conducted on the remaining eligible patients.

The clinical, pathologic, or immunohistochemical (IHC) data were collected. According to the IHC profile, molecular subtypes were classified as follows: luminal (positive for estrogen receptor \[ER\] or progesterone receptor \[PR\], and negative for human epidermal growth factor receptor 2 \[HER2\]), luminal/HER2+ (positive for ER or PR and positive for HER2), HER2+/ER-PR- (negative for ER/PR and positive for HER2), and triple-negative (negative for all ER, PR, and HER2) \[[@B15]\].

Local recurrence (LR) was defined as tumor reappearance in the ipsilateral breast; regional recurrence (RR) as recurrence in axilla, internal mammary area, infraclavicular or supraclavicular regions; and locoregional recurrence (LRR) as either LR or RR. DM was defined as tumor recurrence outside the above locoregional areas. Biopsy or excision was performed if additional pathologic and/or IHC examination was needed for optimal systemic management or if solitary LRR was suspected; however, either clinical or radiologic examination alone was sufficient to diagnose recurrence in patients who had a poor performance status and/or multiple sites or multiple lesions.

The Fisher exact test and Mann-Whitney test were used to compare clinical, pathologic, or IHC variables between groups. The date of operation was regarded as the start of follow-up for survival analysis. Local recurrence-free survival (LRFS) was measured from the date of the operation to the date when LR developed or the final follow-up visit if LR was not detected during the follow-up period.

To compare the LRFS of the PORT-omission group and the control group who received PORT, subjects were selected from pooled data of 1,015 patients with invasive ductal carcinoma and 56 patients with invasive lobular carcinoma treated between 1994 and 2007 at our institution. Patients who received neoadjuvant chemotherapy before surgery were excluded from the control group. The pathologic stage was I in 588 cases (54.9%), II in 433 (40.4%), and III in 50 (4.7%).

The Kaplan-Meier method and log-rank test were used to calculate survival curves and compare differences between the curves, respectively. All statistical analyses were performed using the Windows version of PASW software version 21.0 (SPSS Inc., Armonk, USA), and *p*\<0.05 was considered statistically significant.

RESULTS
=======

Study population
----------------

During the study period, a total of 6,680 patients received BCS with curative intent at Samsung Medical Center. Among them, BCS was conducted as a primary treatment without RT within 1 year at our institution for 1,210 female patients with invasive breast cancer. Of these, 1,088 patients received PORT at other institutions. Therefore, 122 patients who definitely did not receive PORT remained eligible for this study. Among these patients, an uncontrolled prior malignancy was present in five patients and one patient committed suicide after surgery. During chemotherapy, recurrence was detected in 18 patients, and two patients died because of possible chemotherapy-related respiratory failure without evidence of tumor recurrence. The present study was conducted with the remaining 96 patients ([Figure 1](#F1){ref-type="fig"}). The median follow-up period of those patients was 17.2 months (range, 0.3-115.1 months).

Patients
--------

Omission of PORT was recommended by the physician for patients with stage I disease and an age more than 70 years (n=13), and it was optionally recommended for those with small tumors with a wide margin (stage T1mi, surgical margin ≥5 mm, ductal carcinoma *in situ* smaller than 1 cm; n=7). These 20 patients formed the recommended group. Seventy-six patients refused PORT, even though their doctor advised PORT after BCS (refused group).

The comparison of patient characteristics between the two groups is shown in [Table 1](#T1){ref-type="table"}. As expected, the recommended group had an advanced age (*p*=0.004), a higher percentage of postmenopausal patients (*p*=0.013), no axillary lymph node (LN) metastasis (*p*\<0.001), and a higher proportion of nuclear grade 3 disease (*p*=0.009). Additionally, in the molecular subtype classification, the recommended group showed a higher proportion of the luminal type, and lower proportions of luminal/HER2+ and triple-negative types than the refused group (*p*=0.041).

Because of the older age of the patients and the small tumor size, adjuvant chemotherapy was not used in the recommended group, in contrast to the refused group (*p*=0.003). Endocrine therapy, however, was more frequently used in the recommended group than in the refused group (*p*=0.001), although the positivity status of hormone receptors was not significantly different between the groups.

Proportion of postoperative radiotherapy omission
-------------------------------------------------

The proportion of PORT omission after BCS from the relevant study period was calculated based on our institutional breast cancer database and was classified by surgery type. The overall rate of PORT omission between January 2003 and June 2013 was 1.4% (96 of 6,680 BCS cases). The annual proportion of PORT omission for all patients and separately for the two groups is shown in [Figure 2](#F2){ref-type="fig"}. The data showed a slight increase in the PORT omission rate to approximately 1.5% after 2006, when physicians started to recommend PORT omission in certain cases.

Patterns of recurrence and salvage treatment
--------------------------------------------

LR with or without RR was the most frequent failure pattern in the study patients. Overall, 12 recurrences, developed during the follow-up period, and they were all in the refused group. Among the 12, five were solitary LR only and five were LRR. The other two patients showed DM, one of which was combined with LRR. The median time to recurrence was 9.8 months (range, 6.4-50.2 months).

Nine of the patients who showed LRR were recommended for salvage surgery with adjuvant RT and chemotherapy; the remaining patient showed recurrence on the breast, axilla, and internal mammary LN and underwent salvage RT followed by chemotherapy. Only four patients received the recommended treatment; three of these had no evidence of recurrence during the median follow-up of 18.9 months (range, 17.5-43.0 months), whereas the other patient showed DM after 20 months. Two patients received surgical resection only and refused to undergo RT and chemotherapy; one showed recurrence after 8.9 months, and the other was lost to follow-up 1 month after surgery. The remaining four patients who showed LRR refused to get any treatment and were lost to follow-up.

Local recurrence-free survival
------------------------------

The overall LRFS rate of the PORT omission group was 80.0% at 3 years and 75.6% at 5 years; this result was significantly inferior to the result of a recent analysis of 1,071 patients who received PORT after BCS at our institution (*p*\<0.001) ([Figure 3](#F3){ref-type="fig"}).

Most cases of LR developed within 3 years after surgery. Possible prognostic factors related to LRFS are shown in [Table 2](#T2){ref-type="table"}. Significant favorable prognostic factors were histologic grade 1 or 2 (*p*=0.023), no axillary LN metastasis (*p*=0.039), adjuvant endocrine therapy (*p*=0.046), and the recommended group (*p*=0.026). [Figure 4](#F4){ref-type="fig"} shows LRFS curves according to these significant factors.

DISCUSSION
==========

A proportion of patients with breast cancer do not receive PORT after BCS \[[@B16]\], even though its benefit has been repeatedly confirmed by multiple meta-analyses of large, well-designed, randomized, controlled trials \[[@B17],[@B18]\]. PORT after BCS can reduce both LR and DM, thus improving overall survival \[[@B5]\]. Therefore, guidelines recommend PORT as an integral component of breast cancer management after BCS \[[@B5],[@B6]\]. Nonetheless, 10% to 20% of breast cancer patients in the United States do not receive PORT after BCS \[[@B8],[@B16]\].

Several studies have shown that the effect of PORT after BCS on disease recurrence and overall survival with endocrine therapy is minimal in older patients (aged 70 or more) with stage I disease \[[@B13],[@B19]\]. Based on these results, National Comprehensive Cancer Network guidelines now allow PORT omission after BCS in these patients \[[@B6]\].

Breast cancer is one of the most important health-related issues for Korean women \[[@B3],[@B4]\]. Korea has the most rapidly increasing incidence of breast cancer among the nations of the Organization for Economic Co-operation and Development. There is a slight difference in the breast cancer distribution according to age, and patients aged 70 years or older account for only 5% to 6% of all cases of breast cancer in Korea according to data from 2006 to 2010 \[[@B4]\]. In contrast, more than 40% of breast cancer cases developed in women aged 65 years or older in the United States \[[@B1]\]. Because of these unique characteristics, it is necessary to investigate the proportion and clinical outcomes of PORT omission in Korean breast cancer patients.

Although a large number of patients did not receive PORT after BCS in our institution, more than 90% of these received PORT in regional hospitals. Overall, approximately 1.5% of all patients who received BCS did not receive PORT. This rate is extremely low compared with those reported in other countries \[[@B8],[@B9],[@B16],[@B20]\]. The support of the National Health Insurance Service might be an important reason for this high rate of optimal management. Adequate evaluation of breast cancer by the Health Insurance Review and Assessment Service might be another reason for the high compliance with standard treatments.

The results of large randomized trials on PORT omission in a low-risk older population \[[@B13],[@B19]\] predict favorable clinical outcomes for the patients who were recommended PORT omission in the present study, although the small number of cases and short follow-up period preclude a concrete conclusion. Watchful waiting might be an option for these patients. However, optimal indications based on molecular subtype and/or genomic analyses and careful follow-up are recommended \[[@B21],[@B22],[@B23]\], because, even in this subset of patients, the rate of LR is higher in the PORT omission group than in those that receive PORT in randomized trials \[[@B19]\].

As expected, LR was the most important failure pattern in our study population. Interestingly, recurrence developed only in the refused group, although it should be noted that the follow-up period was relatively short. The patients who were recommended for PORT omission did not receive chemotherapy, but all hormone receptor-positive patients received endocrine therapy.

The recurrence rate in the refused group was higher than that reported in a previous prospective trial \[[@B24]\]. This discrepancy might be associated with differences in the use of optimal systemic management. Many patients enrolled in the present study did not follow the physician\'s recommendation about either PORT or systemic management. Chemotherapy was used in less than one-third of patients in the refused group, and endocrine therapy was used in less than one-half of those who were hormone receptor positive. Moreover, some patients refuse salvage treatment or adjuvant treatment even after recurrence, despite their potential to be cured \[[@B25]\]. Noncompliance might be an important issue in these patients.

In the recent report of Badakhashi et al. \[[@B9]\], the compliance with PORT was closely related with usage of endocrine therapy, and the 5-year LRFS in the noncompliance group was 75.4%. Although a direct comparison of this recurrence rate with that in our study is not possible because other important factors, such as stage or grade, were not matched, the absolute value was very similar to our 5-year LRFS of 75.5%.

To improve clinical outcomes, therefore, overcoming patient noncompliance might be one of the most important issues. More detailed, accurate explanations of the effect and/or necessity of PORT, consequence of clinical outcomes, and recommended alternatives should be provided to allow the patient to contribute to decision making regarding the optimal management strategy.

This study has several limitations. First, selection bias is inevitable because of the retrospective study design and involvement of a single institution. Second, clinical outcomes of some patients could not be assessed because of early follow-up loss, although the records of all patients who did not receive PORT were analyzed. Third, the assessment of survival outcomes, especially in patients with LR, was not conducted owing to the tendency of early follow-up loss of these patients.

To our knowledge, this is the first report describing the clinical outcomes of PORT omission after BCS in a Korean population. The rate of PORT omission was very low among women who underwent surgery in the present study compared with that of other studies worldwide. Our data indicate that PORT might be safely omitted in carefully selected patients aged 70 years or older. However, the rate of LR was dramatically elevated in the refused group, and solutions to enhance compliance in these patients should be discussed.
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![Annual proportion of postoperative radiotherapy (PORT) omission after breast-conserving surgery (BCS). The rate increased slightly to approximately 1.5% after 2006, when physicians started to recommend PORT omission.](jbc-18-50-g002){#F2}
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###### Characteristics of patients according to type of postoperative radiotherapy omission

![](jbc-18-50-i001)

  Variable                Recommend (n = 20) No. (%)   Refuse (n = 76) No. (%)   *p*-value
  ----------------------- ---------------------------- ------------------------- -----------
  Age (yr)^\*^            77 (27-88)                   47 (26-88)                0.004
  Menopausal status                                                              0.013
   Premenopausal          6 (30.0)                     47 (61.8)                 
   Postmenopausal         14 (70.0)                    29 (38.2)                 
  T stage                                                                        0.064
   T1                     17 (85.0)                    47 (61.8)                 
   T2                     3 (15.0)                     29 (38.2)                 
  ALN metastasis                                                                 \<0.001
   Yes                    0                            32 (42.1)                 
   No                     20 (100.0)                   44 (57.9)                 
  Histologic grade                                                               0.064
   1-2                    17 (85.0)                    47 (61.8)                 
   3                      3 (15.0)                     29 (38.2)                 
  Nuclear grade                                                                  0.009
   1-2                    18 (90.0)                    45 (59.2)                 
   3                      2 (10.0)                     31 (40.8)                 
  ER^†^                                                                          0.546
   Positive               15 (83.3)                    56 (73.7)                 
   Negative               3 (16.7)                     20 (26.3)                 
  PR^†^                                                                          0.258
   Positive               15 (83.3)                    52 (68.4)                 
   Negative               3 (16.7)                     24 (31.6)                 
  HER2^†^                                                                        0.451
   Positive               1 (6.3)                      12 (16.0)                 
   Negative               15 (93.8)                    63 (84.0)                 
  Molecular subtype^‡^                                                           0.041
   Luminal A like         12 (50.0)                    33 (43.4)                 
   Luminal/HER2+          3 (15.0)                     23 (30.3)                 
   HER2+/ER-PR-           1 (5.0)                      2 (2.6)                   
   Triple-negative        1 (5.0)                      16 (21.1)                 
   Not defined            3 (15.0)                     2 (2.6)                   
  Adjuvant chemotherapy                                                          0.003
   Yes                    0                            23 (30.3)                 
   No                     20 (100.0)                   53 (69.7)                 
  Endocrine therapy                                                              0.001
   Yes                    15 (75.0)                    25 (32.9)                 
   No                     5 (25.0)                     51 (67.1)                 

ALN=axillary lymph node; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth receptor 2.

^\*^Median (range); ^†^Analysis was performed in only accessible patients (ER/PR examinations were not possible due to no residual tumor after breast-conserving surgery in referred patients or no additional fluorescence *in situ* hybridization in HER2); ^‡^Luminal A like (positive for ER or PR, and negative for HER2); luminal/HER2+ (positive for ER or PR, and positive for HER2); HER2+/ER-PR- (negative for ER/PR, and positive for HER2); triple-negative (negative for all ER, PR, and HER2).

###### Possible prognostic factors predicting local recurrence-free survival

![](jbc-18-50-i002)

  Variable            No.   3-yr LRFS (%)   *p*-value
  ------------------- ----- --------------- -----------
  Age (yr)                                  0.859
   ≤35                8     75              
   \>35               88    80.5            
  pT-stage                                  0.33
   1                  64    84.3            
   2                  32    66.5            
  ALN metastasis                            0.039
   No                 64    84              
   Yes                32    71.1            
  Histologic grade                          0.023
   1-2                64    89.7            
   3                  32    54.4            
  Nuclear grade                             0.241
   1-2                63    87.2            
   3                  33    64.2            
  Molecular subtype                         0.525
   Luminal A like     45    86.7            
   Other              51    72.3            
  Chemotherapy                              0.783
   Yes                23    83.3            
   No                 72    78.6            
  Endocrine therapy                         0.046
   Yes                40    88.6            
   No                 55    67.3            
  PORT omission                             0.026
   Recommended        20    100             
   Refused            76    72.5            

LRFS=local recurrence-free survival; ALN=axillary lymph node; PORT=postoperative radiotherapy.
